I understand your point, but don't you think if ADXS still planned on going it all alone to the finish line that DOC might still be here? DOC seemed to be the primary force behind the go it alone to the bitter end strategy?
"when someone else could easily come into the bidding for Axal after approved, and the price to play will be 10 fold."
That's not how it works Blue. A deal struck now will have a large milestone payment that is triggered if FDA approval is granted, so whether a deal is struck now or after approval the terms and monetary value to ADXS would likely be similar.
blue, manufacturing does not equal sales and marketing. they are not the same. the marketing must be in place for approval and why would you apply, and risk being turned down, if you did not have a partner in place for sales/marketing?